Almirall suffers 9 percent net sales slide in 2011

Almirall's financial results for the first half of 2011 show the company decreased net sales by 9.1 percent compared to the same period in 2010.

Eduardo Sanchiz, chief executive officer of the firm, noted the ramp-up of new products like Silodyx and Conbriza, while pointing out that Sativex and Actikerall also recently made their international debut.

He said: "The first half of the year reflects a material improvement in P&L trends versus the first quarter and we maintain a solid financial position and steady free cash flow generation that provides strategic flexibility."

Net sales for the six-month period decreased to 426 million euros (371 million pounds) from 469 million euros, while normalised net income fell 21.5 per cent to 68.6 million euros.

Mr Sanchiz highlighted how the rest of the year will see several new products launched and stressed the importance of long-term sustainable growth.

The statement follows news that Almirall has submitted a Marketing Authorisation Application for aclidinium bromide to the European Medicines Agency.